Roland Ye
Good morning, everyone. Welcome. We’re excited to be continuing our 44th Annual JPMorgan Healthcare Conference. My name is Roland Ye. I’m associate on the health care investment banking team. And today, it’s my pleasure to introduce Corbus Pharmaceuticals and CEO, Yuval Cohen. We’ll have time for Q&A at the end. And with that, we’ll hand it over to Yuval.
Yuval Cohen
CEO & Director
Good morning, everyone. Roland, thank you so much for that introduction. It’s a delight to be here. We’re very grateful to the JPMorgan team for hosting us again. I’m going to focus this morning on 2 of our assets. I’ll start with important milestones coming up this year for our ADC. And then I’ll talk a bit more about a refresher of our recent obesity data and the milestone there. I’m assuming everyone in this room and probably everyone listening knows the background of Corbus, understands our pipeline. So let’s dive straight into it.
The key questions, I think, for CRB-701 in 2026 are the following, and I’ll divide it into the 3 possible indications of this study — of this drug. The first one revolves around our second-line monotherapy in head and neck. We presented updated data on that at ESMO. We have more and more patients. The duration is getting longer and longer, but it’s still an earlier data set that we presented from this September data cut.
Later this year at a large oncology conference, our aim is to present the maturing data, where the key question revolves around the duration of response for these patients. I think we’ve established that
